211 related articles for article (PubMed ID: 26416355)
1. Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.
Slabáková E; Kharaishvili G; Smějová M; Pernicová Z; Suchánková T; Remšík J; Lerch S; Straková N; Bouchal J; Král M; Culig Z; Kozubík A; Souček K
Oncotarget; 2015 Nov; 6(34):36156-71. PubMed ID: 26416355
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
3. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
4. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.
Chou CC; Lee KH; Lai IL; Wang D; Mo X; Kulp SK; Shapiro CL; Chen CS
Cancer Res; 2014 Sep; 74(17):4783-95. PubMed ID: 24994714
[TBL] [Abstract][Full Text] [Related]
5. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
6. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.
Li QQ; Xu JD; Wang WJ; Cao XX; Chen Q; Tang F; Chen ZQ; Liu XP; Xu ZD
Clin Cancer Res; 2009 Apr; 15(8):2657-65. PubMed ID: 19336515
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
9. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer.
Wang QS; Kong PZ; Li XQ; Yang F; Feng YM
Breast Cancer Res; 2015 Feb; 17(1):30. PubMed ID: 25848863
[TBL] [Abstract][Full Text] [Related]
10. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer.
Zhang Z; Yang C; Gao W; Chen T; Qian T; Hu J; Tan Y
Cancer Lett; 2015 Jun; 361(2):240-50. PubMed ID: 25779673
[TBL] [Abstract][Full Text] [Related]
11. Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization.
Cai G; Wu D; Wang Z; Xu Z; Wong KB; Ng CF; Chan FL; Yu S
Oncogene; 2017 Jan; 36(4):546-558. PubMed ID: 27321179
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype.
Li NY; Weber CE; Mi Z; Wai PY; Cuevas BD; Kuo PC
J Am Coll Surg; 2013 Jul; 217(1):17-26; discussion 26. PubMed ID: 23619316
[TBL] [Abstract][Full Text] [Related]
13. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
[TBL] [Abstract][Full Text] [Related]
14. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum protein 29 regulates epithelial cell integrity during the mesenchymal-epithelial transition in breast cancer cells.
Bambang IF; Lee YK; Richardson DR; Zhang D
Oncogene; 2013 Mar; 32(10):1240-51. PubMed ID: 22543584
[TBL] [Abstract][Full Text] [Related]
16. Sox5 induces epithelial to mesenchymal transition by transactivation of Twist1.
Pei XH; Lv XQ; Li HX
Biochem Biophys Res Commun; 2014 Mar; 446(1):322-7. PubMed ID: 24607904
[TBL] [Abstract][Full Text] [Related]
17. LncRNA-Hh Strengthen Cancer Stem Cells Generation in Twist-Positive Breast Cancer via Activation of Hedgehog Signaling Pathway.
Zhou M; Hou Y; Yang G; Zhang H; Tu G; Du YE; Wen S; Xu L; Tang X; Tang S; Yang L; Cui X; Liu M
Stem Cells; 2016 Jan; 34(1):55-66. PubMed ID: 26418365
[TBL] [Abstract][Full Text] [Related]
18. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
19. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
20. Targeting Mdmx to treat breast cancers with wild-type p53.
Haupt S; Buckley D; Pang JM; Panimaya J; Paul PJ; Gamell C; Takano EA; Lee YY; Hiddingh S; Rogers TM; Teunisse AF; Herold MJ; Marine JC; Fox SB; Jochemsen A; Haupt Y
Cell Death Dis; 2015 Jul; 6(7):e1821. PubMed ID: 26181202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
